Literature DB >> 33540022

Solvent-free temperature-facilitated direct extrusion 3D printing for pharmaceuticals.

Magdalena Kuźmińska1, Beatriz C Pereira2, Rober Habashy2, Matthew Peak3, Mohammad Isreb4, Tim D Gough5, Abdullah Isreb6, Mohamed A Alhnan7.   

Abstract

In an era moving towards digital health, 3D printing has successfully proven its applicability in providing personalised medicine through a technology-based approach. Among the different 3D printing techniques, direct extrusion 3D printing has been demonstrated as a promising approach for on demand manufacturing of solid dosage forms. However, it usually requires the use of elevated temperatures and/or the incorporation of an evaporable solvent (usually water). This can implicate the addition of a drying step, which may compromise the integrity of moisture- or temperature-sensitive drugs, and open the door for additional quality control challenges. Here, we demonstrate a new approach that simplifies direct extrusion 3D printing process with the elimination of the post-printing drying step, by merely adding a fatty glyceride, glyceryl monostearate (GMS), to a model drug (theophylline) and permeable water insoluble methacrylate polymers (Eudragit RL and RS). Indeed, rheological studies indicated that the addition of a combination of a plasticiser, (triethyl citrate), and GMS to theophylline: methacrylate polymer blends significantly reduced the extensional viscosity (to <2.5 kPa·Sec) at 90 °C. Interestingly, GMS demonstrated a dual temperature-dependant behaviour by acting both as a plasticiser and a lubricant at printing temperature (90-110 °C), while aiding solidification at room temperature. X-ray powder diffraction indicated incomplete miscibility of GMS within the polymeric matrix at room temperature with the presence of a subtle diffraction peak, at 2(Θ) = 20°. The 3D printed tablets showed acceptable compendial weight and content uniformity as well as sufficient mechanical resistance. In vitro theophylline release from 3D printed tablets was dependant on Eudragit RL:RS ratio. All in all, this work contributes to the efforts of developing a simplified, facile and low-cost 3D printing for small batch manufacturing of bespoke tablets that circumvents the use of high temperature and post-manufacturing drying step.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Direct ink writing; Early phase clinical trials; Material extrusion; Patient-specific; Personalized; Small batch

Mesh:

Substances:

Year:  2021        PMID: 33540022     DOI: 10.1016/j.ijpharm.2021.120305

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  4 in total

1.  Development and Validation of a Novel Tool for Assessing the Environmental Impact of 3D Printing Technologies: A Pharmaceutical Perspective.

Authors:  Souha H Youssef; Sadikalmahdi Abdella; Sanjay Garg
Journal:  Pharmaceutics       Date:  2022-04-25       Impact factor: 6.525

2.  Compounding Tailored Veterinary Chewable Tablets Close to the Point-of-Care by Means of 3D Printing.

Authors:  Erica Sjöholm; Rathna Mathiyalagan; Xiaoju Wang; Niklas Sandler
Journal:  Pharmaceutics       Date:  2022-06-24       Impact factor: 6.525

3.  3D Printing of Drug Nanocrystals for Film Formulations.

Authors:  Giorgia Germini; Leena Peltonen
Journal:  Molecules       Date:  2021-06-28       Impact factor: 4.411

Review 4.  The Advent of a New Era in Digital Healthcare: A Role for 3D Printing Technologies in Drug Manufacturing?

Authors:  Ioannis I Andreadis; Christos I Gioumouxouzis; Georgios K Eleftheriadis; Dimitrios G Fatouros
Journal:  Pharmaceutics       Date:  2022-03-10       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.